CSIMarket Company Name, Ticker, Competitors, else..
 
Aptose Biosciences Inc   (APTO)
Other Ticker:  
 
 
Price: $1.7100 $-1.44 -45.714%
Day's High: $1.99 Week Perf: -51 %
Day's Low: $ 1.35 30 Day Perf: -40 %
Volume (M): 670 52 Wk High: $ 22.50
Volume (M$): $ 1,146 52 Wk Avg: $9.43
Open: $1.99 52 Wk Low: $1.35



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 2
 Employees 13
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Aptose Biosciences Inc
Aptose Biosciences Inc is a Canadian biotech company that specializes in the research and development of targeted therapies for cancer treatment. The company focuses on developing drugs that target specific molecular pathways involved in cancer growth and survival. Aptose Biosciences utilizes innovative technologies and collaborations with academic institutions and industry partners to discover and develop promising treatments. Their goal is to provide effective therapies that improve patient outcomes and address unmet medical needs in oncology.


   Company Address: 66 Wellington Street WestSuite 5300 Toronto 0 ON
   Company Phone Number: 479-9828   Stock Exchange / Ticker: APTO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AGEN      % 
AMGN      % 
CCCC      % 
CRIS      % 
GILD      % 
RLAY      % 
• View Complete Report
   



Shares

Aptose Biosciences Fortifies Financial Arsenal with New $25 Million Equity Facilities: A Strategic Move for Shareholder Value

Published Thu, Feb 13 2025 9:30 PM UTC

Aptose Biosciences Inc. a clinical-stage biotechnology company known for its innovative approaches to cancer therapy, recently announced two significant financial maneuvers designed to strengthen its operational foundation and bolster shareholder confidence. By securing a $25 million committed equity facility and establishing a new at-the-market (ATM) facility, Aptose unders...
Clinical Study

Aptose Demonstrates Promise of Tuspetinib in AML Data Highlights Clinical and Preclinical Advances

Published Thu, Dec 12 2024 3:15 PM UTC

In the dynamic field of cancer research, Aptose Biosciences Inc. is making significant strides with its promising therapeutic candidate, Tuspetinib. Recently, the company announced a series of findings that underline the potential of Tuspetinib as a potent option for the treatment of acute myeloid leukemia (AML), particularly refractory and relapsed cases. The data have been...
Clinical Study

Revamping AML Treatment Aptose Therapeutics Launches TUSCANY Phase 1/2 Study with Tuspetinib Triplet Therapy

Published Wed, Nov 20 2024 12:30 PM UTC

In a groundbreaking development for the treatment of acute myeloid leukemia (AML), Aptose Therapeutics, a leader in oncology innovation, has announced the initiation of the TUSCANY Phase 1/2 study. This pioneering clinical trial aims to evaluate the efficacy and safety of a triplet therapy centered around Tuspetinib, a targeted therapy specifically designed for newly diagnos...
Announcement

Aptoses Ambitious Triplet Therapy A Game Changer for Newly Diagnosed AML Amidst Financial Challenges

Published Fri, Nov 8 2024 9:01 PM UTC

In an era where innovation meets urgency, Aptose Biosciences Inc. is making notable strides in the treatment landscape for newly diagnosed acute myeloid leukemia (AML). In the recently released third quarter results for 2024, Aptose announced an exciting collaboration with Hanmi Pharmaceutical, embarking on a co-development journey of an innovative triplet therapy. This new ...
Partnership

Strengthening Bonds Aptose and Hanmis $10 Million Agreement and Potential Joint Tuspetinib Development...

Published Fri, Aug 30 2024 8:30 PM UTC

: This article outlines the recent financial facilitation between Aptose Biosciences Inc. and Hanmi Pharmaceutical Co. Ltd. alongside ongoing discussions about a prospective joint development effort focused on Tuspetinib, a promising therapeutic candidate. This transaction and negotiation highlight a pivotal step in biopharmaceutical collaboration aimed at advancing cancer t...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com